Humanized GPIbα–von Willebrand factor interaction in the mouse
Open Access
- 4 October 2018
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (19) , 2522-2532
Abstract
The interaction of platelet glycoprotein Ibα (GPIbα) with von Willebrand factor (VWF) initiates hemostasis after vascular injury and also contributes to pathological thrombosis. GPIbα binding to the VWF A1 domain (VWFA1) is a target for antithrombotic intervention, but attempts to develop pharmacologic inhibitors have been hindered by the lack of animal models because of the species specificity of the interaction. To address this problem, we generated a knockin mouse with Vwf exon 28–encoding domains A1 and A2 replaced by the human homolog (VWFh28). VWFh28 mice (M1HA) were crossbred with a transgenic mouse strain expressing human GPIbα on platelets (mGPIbαnull;hGPIbαTg; H1MA) to generate a new strain (H1HA) with humanized GPIbα-VWFA1 binding. Plasma VWF levels in the latter 3 strains were similar to those of wild-type mice (M1MA). Compared with the strains that had homospecific GPIbα-VWF pairing (M1MA and H1HA), M1HA mice of those with heterospecific pairing had a markedly greater prolongation of tail bleeding time and attenuation of thrombogenesis after injury to the carotid artery than H1MA mice. Measurements of GPIbα-VWFA1 binding affinity by surface plasmon resonance agreed with the extent of observed functional defects. Ristocetin-induced platelet aggregation was similar in H1HA mouse and human platelet-rich plasma, and it was comparably inhibited by monoclonal antibody NMC-4, which is known to block human GPIbα-VWFA1 binding, which also inhibited FeCl3-induced mouse carotid artery thrombosis. Thus, the H1HA mouse strain is a fully humanized model of platelet GPIbα-VWFA1 binding that provides mechanistic and pharmacologic information relevant to human hemostatic and thrombotic disorders.Keywords
This publication has 60 references indexed in Scilit:
- In Vivo Analysis of the Role of O-Glycosylations of Von Willebrand FactorPLOS ONE, 2012
- Correction of Murine Bernard–Soulier Syndrome by Lentivirus-mediated Gene TherapyMolecular Therapy, 2012
- The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid EndarterectomyStroke, 2011
- P2X7 receptor signaling contributes to tissue factor–dependent thrombosis in miceJournal of Clinical Investigation, 2011
- Binding of α-thrombin to surface-anchored platelet glycoprotein Ibα sulfotyrosines through a two-site mechanism involving exosite IProceedings of the National Academy of Sciences, 2011
- Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779Journal of Thrombosis and Haemostasis, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Activation-independent platelet adhesion and aggregation under elevated shear stressBlood, 2006
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Antithrombotic effects of AbciximabThe American Journal of Cardiology, 2000